Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Research
  • Published:

Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men

International Journal of Impotence Research volume 17, pages 80–85 (2005)Cite this article

Abstract

Although subgroup analyses from large randomised premarketing studies have shown that Apomorphine SL enhances the percentage of erections firm enough for sexual intercourse in diabetic men, the clinical role of the drug in this patient population remains to be elucidated. The aim of the present study was to assess the efficacy of Apomorphine SL in diabetic males with erectile dysfunction (ED) and to identify factors predicting those who may benefit from the treatment. A total of 130 diabetic patients were randomised to receive either four tablets of 3 mg Apomorphine or a matching placebo. Assessments of efficacy comprised the erectile function (EF) domain of the International Index of Erectile Function (IIEF) and the one-item global efficacy question (GEQ). Patients with both a positive response to the GEQ and an improvement of at least 5 points in the EF domain of the IIEF were considered responders and subanalysed by several parameters indicative of the severity of both ED and diabetes. Response rate was 17% after placebo and 22% after Apomorphine SL. The EF domain of the IIEF and both questions 3 and 4 scores did not significantly improve in either of the two arms over the baseline. A younger age and a lower Hb1Ac were significantly linked to the status of responder in the Apomorphine arm. Apomorphine SL failed to show a statistically significant benefit over a placebo, but 22% of patients had a clinically significant erectile response. These figures seem to suggest that the drug has a limited use for ED diabetic patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Fedele D et al. Incidence of erectile dysfunction in Italian men with diabetes. J Urol 2001; 166: 1368–1371.

    Article  CAS  Google Scholar 

  2. Nicolosi A et al. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology 2003; 61: 201–206.

    Article  Google Scholar 

  3. Moreland RB . Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the society for the study of impotence. Int J Impot Res 1998; 10: 113–120.

    Article  CAS  Google Scholar 

  4. Cartledge JJ, Eardley I, Morrison JF . Advanced glycation products are responsible for the impairment of corpus cavernosal smooth muscle relaxation in diabetes. Br J Urol 2001; 87: 402–407.

    Article  CAS  Google Scholar 

  5. West IC . Radicals and oxidative stress in diabetes. Diabetic Med 2000; 17: 171–180.

    Article  CAS  Google Scholar 

  6. Vickers MA, Satyanarayana R . Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2002; 14: 466–471.

    Article  CAS  Google Scholar 

  7. Lepore G, Nosari I . Efficacy of oral Sildenafil in the treatment of erectile dysfunction in diabetic men with positive response to intracavernosal injection of Alprostadil. Diabetes Care 2001; 24: 409–411.

    Article  CAS  Google Scholar 

  8. Heaton JP, Adams MA, Morales A . A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary perspective. Int J Impot Res 1997; 9: 115–121.

    Article  CAS  Google Scholar 

  9. Stief C, Padley RJ, Perdok RJ, Sleep DJ . Cross-study review of the clinical efficacy of Apomorphine SL 2 and 3 mg: pooled data from three placebo-controlled, fixed-dose crossover studies. Eur Urol 2002; 1: 12–20.

    Article  CAS  Google Scholar 

  10. Dula E, Bukofzer S, Perdok R, George M, the Apomorphine SL Study Group. Double-blind, crossover comparison of 3 mg Apomorphine SL with placebo and with 4 mg Apomorphine SL in male erectile dysfunction. Eur Urol 2000; 39: 558–564.

    Article  Google Scholar 

  11. Mulhall JP, Bukofzer S, Edmonds AL, George M, the Apomorphine SL Study Group. An open-label, uncontrolled dose-optimization study of sublingual Apomorphine in erectile dysfunction. Clin Ther 2001; 23: 1260–1271.

    Article  CAS  Google Scholar 

  12. DeBusk R et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus panel. Am J Cardiol 2000; 86: 175–181.

    Article  CAS  Google Scholar 

  13. Rosen RC, Riley A, Wagner G . The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–825.

    Article  CAS  Google Scholar 

  14. Gontero P et al. Is there an optimal timing for intracavernous PGE1 rehabilitation following nonnerve sparing radical prostatectomy. Results from a hemodynamic perspective study. J Urol 2003; 169: 2166–2169.

    Article  Google Scholar 

  15. Karadeniz T et al. Value of Colour Doppler sonography in the diagnosis of venous impotence. Urol Int 1995; 55: 143–149.

    Article  CAS  Google Scholar 

  16. Virag R, Frydman D, Legman M, Virag H . Intracavernous injection of papaverine as diagnostic and therapeutic method in erectile failure. Angiology 1984; 35: 79–82.

    Article  CAS  Google Scholar 

  17. Breda G et al. Nomogram for penile biothesiometry. Eur Urol 1991; 20: 67–69.

    Article  CAS  Google Scholar 

  18. Heaton JPW . Apomorphine. An update of clinical trial results. Int J Impot Res 2000; 12 (Suppl): S67–73.

    Article  Google Scholar 

  19. Heaton JPW, Dean J, Sleep DJ . Sequential administration enhances the effect of Apomorphine Sl in men with erectile dysfunction. Int J Impot Res 2002; 14: 61–64.

    Article  CAS  Google Scholar 

  20. Boulton AJM, Selam J-L, Sweeney M, Ziegler D . Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 2001; 44: 1296–1301.

    Article  CAS  Google Scholar 

  21. Goldstein I et al. Vardenafil, a new phosphodiesterase type 5 inhibitor in the treatment of erectile dysfunction in diabetic men. Diabetes Care 2003; 26: 777–783.

    Article  CAS  Google Scholar 

  22. Romeo JH, Seftel AD, Madhun ZT, Aron DC . Sexual function in men with diabetes type 2: association with glycemic control. J Urol 2000; 163: 788–791.

    Article  CAS  Google Scholar 

  23. Rendell MS, Rajfer J, Wicker PA, Smith MD . Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 1999; 281: 424–426.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinica Urologica, Universita' Piemonte Orientale, Novara, Italy

    P Gontero, G Pretti, F Fontana, E Kocjancic & B Frea

  2. Divisione di Diabetologia, Ospedale Maggiore della Carita', Novara, Italy

    R D'Antonio & G Allochis

  3. Department of Public Health, Universita' Piemonte Orientale, Novara, Italy

    M Panella

Authors
  1. P Gontero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R D'Antonio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Pretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Fontana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Panella
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Kocjancic
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Allochis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B Frea
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Gontero.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gontero, P., D'Antonio, R., Pretti, G. et al. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men. Int J Impot Res 17, 80–85 (2005). https://doi.org/10.1038/sj.ijir.3901273

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901273

Keywords

This article is cited by

Search

Advanced search

Quick links